In a highly dynamic and fragmented pharmaceutical market, besieged by intense competition, rapid pace of technological innovations and the uncertainty regarding future government regulations, the ability to anticipate new competitive product introductions and marketing strategies is particularly important... and spells the difference between success and failure. The TOP 10, a unique series of market intelligence studies first introduced in 1987, is designed to provide the pharmaceutical industry executives, as well as companies planning to diversify into the pharmaceutical field, with strategically significant competitor information, analysis and insight, critical to the development and implementation of effective marketing and R&D programs. The study's major objectives include: to establish a comprehensive, factual, annually-updated and cost-effective; information base on performance, capabilities, goals and strategies of the world's leading pharmaceutical companies; to help current suppliers realistically assess their financial, marketing and technological capabilities vis-a-vis leading competitors; to assist potential market entrants in evaluating prospective acquisitions and joint venture candidates; and to complement organizations' internal competitor information gathering efforts by providing strategic analysis, data interpretation and insight.

The study provides an approximately 50-page worldwide strategic overview of the pharmaceutical market, including sales forecast for major product segments (ethical, OTC, generics); key geographic regions (North America, Western Europe, Japan, Eastern Europe, and Latin America); major drug categories, including cardiovascular, gastrointestinal, antibiotics, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, and others. In addition, the report reviews major U.S. and international regulatory, technological, economic, demographic, and social trends with potentially significant impact on the pharmaceutical industry during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies.

The report provides: Executive Summary; Business Organization; Senior Management; Facilities and Employees; Technological Know-How; Product Portfolio Analysis; Marketing Tactics; Financial Analysis; R&D Expenditures and Major Programs; Collaborative Arrangements; and Strategic Direction.

For more information visit http://www.researchandmarkets.com/research/0c55f5/the_top_10_worlds